At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 61 enrolled
Drug / intervention
Lurasidone 80mg tabletdrug
Likely dose
Lurasidone 80 mg tabletAI-extracted
Key inclusion· 2
- ✓Prior participation in study D1050196 (schizophrenia efficacy/safety study)
- ✓Either successfully completed D1050196 or discontinued after minimum 2 weeks due to lack of efficacy
Key exclusion· 0
None specified.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Multicenter, Twelve-Month Study of Safety and Tolerability in the Treatment of Schizophrenia
In Brief
A Phase 2 clinical trial evaluating Lurasidone 80mg tablet for Schizophrenia. Completed, enrolled 61 participants across 21 sites.
Detailed Summary
A 1-year outpatient study to test the safety and tolerability of a new medication in the treatment of schizophrenia
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2004
First PostedAug 2004
Primary CompletionOct 2005
TodayJul 2026
First PostedAug 2, 2004
Enrollment StartJul 1, 2004
Primary CompletionOct 1, 2005
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 21.9 years ago
Interventions
Lurasidone 80mg tabletdrug